The DOI matches its Crossref record; 258 of the 258 references it cites were found in a registry or an index.
JAK/STAT pathway: Extracellular signals, diseases, immunity, and therapeutic regimens
Open accessAbstract
Janus kinase/signal transduction and transcription activation (JAK/STAT) pathways were originally thought to be intracellular signaling pathways that mediate cytokine signals in mammals. Existing studies show that the JAK/STAT pathway regulates the downstream signaling of numerous membrane proteins such as such as G-protein-associated receptors, integrins and so on. Mounting evidence shows that the JAK/STAT pathways play an important role in human disease pathology and pharmacological mechanism. The JAK/STAT pathways are related to aspects of all aspects of the immune system function, such as fighting infection, maintaining immune tolerance, strengthening barrier function, and cancer prevention, which are all important factors involved in immune response. In addition, the JAK/STAT pathways play an important role in extracellular mechanistic signaling and might be an important mediator of mechanistic signals that influence disease progression, immune environment. Therefore, it is important to understand the mechanism of the JAK/STAT pathways, which provides ideas for us to design more drugs targeting diseases based on the JAK/STAT pathway. In this review, we discuss the role of the JAK/STAT pathway in mechanistic signaling, disease progression, immune environment, and therapeutic targets.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Ruan, Z., Yang, X., & Cheng, W. (2018) · Cancer Management and Research · doi:10.2147/cmar.s180418 · Cited by 54
RetractedMyeloid-derived-suppressor cells as regulators of the immune system
Gabrilovich, D. I., & Nagaraj, S. (2009) · Nature Reviews Immunology · doi:10.1038/nri2506 · Cited by 6,753
STATs in cancer inflammation and immunity: a leading role for STAT3
Yu, H., Pardoll, D., & Jove, R. (2009) · Nature reviews. Cancer · doi:10.1038/nrc2734 · Cited by 4,383
New insights into the mechanisms of epithelial–mesenchymal transition and implications for cancer
Dongre, A., & Weinberg, R. A. (2019) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-018-0080-4 · Cited by 3,876
Tumour stem cells and drug resistance
Dean, M., Fojo, T., & Bates, S. (2005) · Nature reviews. Cancer · doi:10.1038/nrc1590 · Cited by 3,668
M-1/M-2 Macrophages and the Th1/Th2 Paradigm
Mills, C. D., Kincaid, K., Alt, J. M., Heilman, M. J., & Hill, A. M. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.12.6166 · Cited by 3,287
Targeting the IL-6/JAK/STAT3 signalling axis in cancer
Johnson, D. E., O'Keefe, R. A., & Grandis, J. R. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2018.8 · Cited by 3,110
The biology of human natural killer-cell subsets
Cooper, M. A., Fehniger, T. A., & Caligiuri, M. A. (2001) · Trends in Immunology · doi:10.1016/s1471-4906(01)02060-9 · Cited by 2,975
IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity
Shankaran, V., Ikeda, H., Bruce, A. T., White, J. M., Swanson, P. E., Old, L. J., & Schreiber, R. D. (2001) · Nature · doi:10.1038/35074122 · Cited by 2,896
EMT, CSCs, and drug resistance: the mechanistic link and clinical implications
Shibue, T., & Weinberg, R. A. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.44 · Cited by 2,539 · cited 1×
“Studies have shown that cancer stem cells have been proposed to explain the development of cancer and resistance to treatment, and activation of the JAK/STAT signalling pathway, or induction of other signals that interact with the JAK/STAT pathway, can promote the production and acquisition of drug resistance by cance…”
BackgroundAngiotensin II cell signaling: physiological and pathological effects in the cardiovascular system
Mehta, P. K., & Griendling, K. K. (2007) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00287.2006 · Cited by 1,924
Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment
Yu, H., Kortylewski, M., & Pardoll, D. (2007) · Nature Reviews Immunology · doi:10.1038/nri1995 · Cited by 1,804
The JAK-STAT Pathway: Impact on Human Disease and Therapeutic Intervention
O'Shea, J. J., Schwartz, D. M., Villarino, A. V., Gadina, M., McInnes, I. B., & Laurence, A. (2015) · Annual Review of Medicine · doi:10.1146/annurev-med-051113-024537 · Cited by 1,599
The Hippo Pathway: Biology and Pathophysiology
Ma, S., Meng, Z., Chen, R., & Guan, K.-L. (2019) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-013118-111829 · Cited by 1,387 · cited 1×
“These physical interactions continuously transmit extracellular signals to the cell nucleus, which have multiple and profound effects on numerous biological processes including membrane proteins (Dalton and Lemmon, 2021), intracellular organelles (Ma et al., 2019), nuclear transcription and translation processes (Grah…”
BackgroundIFNα activates dormant haematopoietic stem cells in vivo
Essers, M. A. G., Offner, S., Blanco-Bose, W. E., Waibler, Z., Kalinke, U., Duchosal, M. A., & Trumpp, A. (2009) · Nature · doi:10.1038/nature07815 · Cited by 1,368 · cited 2×
“DCs are produced by hematopoietic progenitor cells (such as CDP) under the control of exogenous cytokine signals and intrinsic transcriptional regulators (Collin and Ginhoux, 2019).”
BackgroundMovahedi, K., Guilliams, M., Van den Bossche, J., Van den Bergh, R., Gysemans, C., Beschin, A., De Baetselier, P., & Van Ginderachter, J. A. (2008) · Blood · doi:10.1182/blood-2007-07-099226 · Cited by 1,234
Banerjee, S., Biehl, A., Gadina, M., Hasni, S., & Schwartz, D. M. (2017) · Drugs · doi:10.1007/s40265-017-0701-9 · Cited by 1,206
The JAK-STAT Signaling Pathway: Input and Output Integration
Murray, P. J. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.5.2623 · Cited by 1,179
Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells
Wang, T., Niu, G., Kortylewski, M., Burdelya, L., Shain, K., Zhang, S., Bhattacharya, R., Gabrilovich, D., Heller, R., Coppola, D., et al. (2004) · Nature Medicine · doi:10.1038/nm976 · Cited by 1,155
Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity
Kortylewski, M., Kujawski, M., Wang, T., Wei, S., Zhang, S., Pilon-Thomas, S., Niu, G., Kay, H., Mulé, J., Kerr, W. G., et al. (2005) · Nature Medicine · doi:10.1038/nm1325 · Cited by 1,031
IL-23 promotes tumour incidence and growth
Langowski, J. L., Zhang, X., Wu, L., Mattson, J. D., Chen, T., Smith, K., Basham, B., McClanahan, T., Kastelein, R. A., & Oft, M. (2006) · Nature · doi:10.1038/nature04808 · Cited by 1,018 · cited 1×
“IL-6 induces STAT3-mediated Th17 differentiation, which maintains inflammatory responses by releasing IL-17 and IL-23 and causes the secretion of VEGF and TGF in fibroblasts and endothelial cells (Langowski et al., 2006; Wang L. et al., 2009).”
BackgroundThe role of JAK/STAT signaling pathway and its inhibitors in diseases.
Xin, P., Xu, X., Deng, C., Liu, S., Wang, Y., Zhou, X., Ma, H., Wei, D., & Sun, S. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106210 · Cited by 1,010 · cited 1×
“cytokines, which regulates gene expression and cell activation, proliferation, and differentiation (Reddy et al., 2019; Xin et al., 2020; Awasthi et al., 2021).”
BackgroundIL-17 can promote tumor growth through an IL-6–Stat3 signaling pathway
Wang, L., Yi, T., Kortylewski, M., Pardoll, D. M., Zeng, D., & Yu, H. (2009) · Journal of Experimental Medicine · doi:10.1084/jem.20090207 · Cited by 842
Self-citationBurchill, M. A., Yang, J., Vogtenhuber, C., Blazar, B. R., & Farrar, M. A. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.1.280 · Cited by 834
Interleukin-6 Family Cytokines
Rose-John, S. (2018) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a028415 · Cited by 799
Zorn, E., Nelson, E. A., Mohseni, M., Porcheray, F., Kim, H., Litsa, D., Bellucci, R., Raderschall, E., Canning, C., Soiffer, R. J., et al. (2006) · Blood · doi:10.1182/blood-2006-02-004747 · Cited by 740
Diverse Targets of the Transcription Factor STAT3 Contribute to T Cell Pathogenicity and Homeostasis
Durant, L., Watford, W. T., Ramos, H. L., Laurence, A., Vahedi, G., Wei, L., Takahashi, H., Sun, H.-W., Kanno, Y., Powrie, F., et al. (2010) · Immunity · doi:10.1016/j.immuni.2010.05.003 · Cited by 726
T-helper-1-cell cytokines drive cancer into senescence
Braumüller, H., Wieder, T., Brenner, E., Aßmann, S., Hahn, M., Alkhaled, M., Schilbach, K., Essmann, F., Kneilling, M., Griessinger, C., et al. (2013) · Nature · doi:10.1038/nature11824 · Cited by 720
Persistently Activated Stat3 Maintains Constitutive NF-κB Activity in Tumors
Lee, H., Herrmann, A., Deng, J.-H., Kujawski, M., Niu, G., Li, Z., Forman, S., Jove, R., Pardoll, D. M., & Yu, H. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.02.015 · Cited by 683
Sadoshima, J., & Izumo, S. (1993) · The EMBO Journal · doi:10.1002/j.1460-2075.1993.tb05813.x · Cited by 667
Nguyen, K. B., Salazar-Mather, T. P., Dalod, M. Y., Van Deusen, J. B., Wei, X.-Q., Liew, F. Y., Caligiuri, M. A., Durbin, J. E., & Biron, C. A. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.8.4279 · Cited by 610
Re-Engineering Extracellular Vesicles as Smart Nanoscale Therapeutics
Armstrong, J. P. K., Holme, M. N., & Stevens, M. M. (2017) · ACS Nano · doi:10.1021/acsnano.6b07607 · Cited by 602
Banerjee, S., Biehl, A., Gadina, M., Hasni, S., & Schwartz, D. M. (2017) · Drugs · doi:10.1007/s40265-017-0736-y · Cited by 590
Stat3 mediates myeloid cell–dependent tumor angiogenesis in mice
Kujawski, M., Kortylewski, M., Lee, H., Herrmann, A., Kay, H., & Yu, H. (2008) · Journal of Clinical Investigation · doi:10.1172/jci35213 · Cited by 581
Mechanisms of Jak/STAT Signaling in Immunity and Disease
Villarino, A. V., Kanno, Y., Ferdinand, J. R., & O’Shea, J. J. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1401867 · Cited by 552
Akt‐mediated regulation of NFκB and the essentialness of NFκB for the oncogenicity of PI3K and Akt
Bai, D., Ueno, L., & Vogt, P. K. (2009) · International Journal of Cancer · doi:10.1002/ijc.24748 · Cited by 529
The JAK2 Inhibitor AZD1480 Potently Blocks Stat3 Signaling and Oncogenesis in Solid Tumors
Hedvat, M., Huszar, D., Herrmann, A., Gozgit, J. M., Schroeder, A., Sheehy, A., Buettner, R., Proia, D., Kowolik, C. M., Xin, H., et al. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.10.015 · Cited by 526
Self-citationIL-6 regulates in vivo dendritic cell differentiation through STAT3 activation
Park, S.-J., Nakagawa, T., Kitamura, H., Atsumi, T., Kamon, H., Sawa, S.-I., Kamimura, D., Ueda, N., Iwakura, Y., Ishihara, K., et al. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.6.3844 · Cited by 519
Interferon-γ derived from cytotoxic lymphocytes directly enhances their motility and cytotoxicity
Bhat, P., Leggatt, G., Waterhouse, N., & Frazer, I. H. (2017) · Cell Death & Disease · doi:10.1038/cddis.2017.67 · Cited by 515
Wang, T.-T., Zhao, Y.-L., Peng, L.-S., Chen, N., Chen, W., Lv, Y.-P., Mao, F.-Y., Zhang, J.-Y., Cheng, P., Teng, Y.-S., et al. (2017) · Gut · doi:10.1136/gutjnl-2016-313075 · Cited by 509
STAT3 regulates arginase-I in myeloid-derived suppressor cells from cancer patients
Vasquez-Dunddel, D., Pan, F., Zeng, Q., Gorbounov, M., Albesiano, E., Fu, J., Blosser, R. L., Tam, A. J., Bruno, T., Zhang, H., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci60083 · Cited by 507
Mechanical stress-induced cardiac hypertrophy: mechanisms and signal transduction pathways
Ruwhof, C. (2000) · Cardiovascular Research · doi:10.1016/s0008-6363(00)00076-6 · Cited by 505
Direct Effects of Type I Interferons on Cells of the Immune System
Hervas-Stubbs, S., Perez-Gracia, J. L., Rouzaut, A., Sanmamed, M. F., Le Bon, A., & Melero, I. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1114 · Cited by 503
Dendritic Cells and Their Role in Immunotherapy
Gardner, A., de Mingo Pulido, Á., & Ruffell, B. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00924 · Cited by 485
A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo
Levis, M., Allebach, J., Tse, K.-F., Zheng, R., Baldwin, B. R., Smith, B. D., Jones-Bolin, S., Ruggeri, B., Dionne, C., & Small, D. (2002) · Blood · doi:10.1182/blood.v99.11.3885 · Cited by 475
Regulation of the IL-23 and IL-12 Balance by Stat3 Signaling in the Tumor Microenvironment
Kortylewski, M., Xin, H., Kujawski, M., Lee, H., Liu, Y., Harris, T., Drake, C., Pardoll, D., & Yu, H. (2009) · Cancer Cell · doi:10.1016/j.ccr.2008.12.018 · Cited by 474
ROCK and Dia have opposing effects on adherens junctions downstream of Rho
Sahai, E., & Marshall, C. J. (2002) · Nature Cell Biology · doi:10.1038/ncb796 · Cited by 466
Stretching cardiac myocytes stimulates protooncogene expression.
Komuro, I., Kaida, T., Shibazaki, Y., Kurabayashi, M., Katoh, Y., Hoh, E., Takaku, F., & Yazaki, Y. (1990) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)39631-0 · Cited by 460
Cao, Y., Wei, J., Zou, L., Jiang, T., Wang, G., Chen, L., Huang, L., Meng, F., Huang, L., Wang, N., et al. (2020) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2020.05.019 · Cited by 456
STAT1 Signaling Regulates Tumor-Associated Macrophage-Mediated T Cell Deletion
Kusmartsev, S., & Gabrilovich, D. I. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.8.4880 · Cited by 445
Immune Response in Stat2 Knockout Mice
Park, C., Li, S., Cha, E., & Schindler, C. (2000) · Immunity · doi:10.1016/s1074-7613(00)00077-7 · Cited by 415
Role of Stat3 in Regulating p53 Expression and Function
Niu, G., Wright, K. L., Ma, Y., Wright, G. M., Huang, M., Irby, R., Briggs, J., Karras, J., Cress, W. D., Pardoll, D., et al. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.17.7432-7440.2005 · Cited by 392
Type I interferon response and innate immune sensing of cancer
Fuertes, M. B., Woo, S.-R., Burnett, B., Fu, Y.-X., & Gajewski, T. F. (2013) · Trends in Immunology · doi:10.1016/j.it.2012.10.004 · Cited by 375
Banes, A. J., Tsuzaki, M., Yamamoto, J., Brigman, B., Fischer, T., Brown, T., & Miller, L. (1995) · Biochemistry and Cell Biology · doi:10.1139/o95-043 · Cited by 369
Activation and Association of Stat3 with Src in v-Src-Transformed Cell Lines
Cao, X., Tay, A., Guy, G. R., & Tan, Y. H. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.4.1595 · Cited by 359
Gouilleux, F., Pallard, C., Dusanter-Fourt, I., Wakao, H., Haldosen, L. A., Norstedt, G., Levy, D., & Groner, B. (1995) · The EMBO Journal · doi:10.1002/j.1460-2075.1995.tb07192.x · Cited by 358
Loh, C.-Y., Arya, A., Naema, A. F., Wong, W. F., Sethi, G., & Looi, C. Y. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00048 · Cited by 348
The role of STAT3 in leading the crosstalk between human cancers and the immune system
Wang, Y., Shen, Y., Wang, S., Shen, Q., & Zhou, X. (2018) · Cancer Letters · doi:10.1016/j.canlet.2017.12.003 · Cited by 340
STAT3 is required for Flt3L-dependent dendritic cell differentiation
Laouar, Y., Welte, T., Fu, X.-Y., & Flavell, R. A. (2003) · Immunity · doi:10.1016/s1074-7613(03)00332-7 · Cited by 334
Mimura, K., Teh, J. L., Okayama, H., Shiraishi, K., Kua, L., Koh, V., Smoot, D. T., Ashktorab, H., Oike, T., Suzuki, Y., et al. (2018) · Cancer Science · doi:10.1111/cas.13424 · Cited by 329
Interleukin-2, Interleukin-15, and Their Roles in Human Natural Killer Cells
Becknell, B., & Caligiuri, M. A. (2005) · Advances in Immunology · doi:10.1016/s0065-2776(04)86006-1 · Cited by 325
Stat5b Is Essential for Natural Killer Cell–mediated Proliferation and Cytolytic Activity
Imada, K., Bloom, E. T., Nakajima, H., Horvath-Arcidiacono, J. A., Udy, G. B., Davey, H. W., & Leonard, W. J. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.188.11.2067 · Cited by 325
PD‐L1 expression on tolerogenic APCs is controlled by STAT‐3
Wölfle, S. J., Strebovsky, J., Bartz, H., Sähr, A., Arnold, C., Kaiser, C., Dalpke, A. H., & Heeg, K. (2011) · European Journal of Immunology · doi:10.1002/eji.201040979 · Cited by 323
Fibronectin: Molecular Structure, Fibrillar Structure and Mechanochemical Signaling
Dalton, C. J., & Lemmon, C. A. (2021) · Cells · doi:10.3390/cells10092443 · Cited by 319
Phase Separation of a PKA Regulatory Subunit Controls cAMP Compartmentation and Oncogenic Signaling
Zhang, J. Z., Lu, T.-W., Stolerman, L. M., Tenner, B., Yang, J. R., Zhang, J.-F., Falcke, M., Rangamani, P., Taylor, S. S., Mehta, S., et al. (2020) · Cell · doi:10.1016/j.cell.2020.07.043 · Cited by 314
Mechanical Stretch Activates the JAK/STAT Pathway in Rat Cardiomyocytes
Pan, J., Fukuda, K., Saito, M., Matsuzaki, J., Kodama, H., Sano, M., Takahashi, T., Kato, T., & Ogawa, S. (1999) · Circulation Research · doi:10.1161/01.res.84.10.1127 · Cited by 312
Yang, J., Liao, D., Chen, C., Liu, Y., Chuang, T.-H., Xiang, R., Markowitz, D., Reisfeld, R. A., & Luo, Y. (2013) · Stem Cells · doi:10.1002/stem.1281 · Cited by 301
STAT‐mediated EGFR signaling in cancer
Quesnelle, K. M., Boehm, A. L., & Grandis, J. R. (2007) · Journal of Cellular Biochemistry · doi:10.1002/jcb.21475 · Cited by 295
Matthews, B. D., Thodeti, C. K., Tytell, J. D., Mammoto, A., Overby, D. R., & Ingber, D. E. (2010) · Integrative Biology · doi:10.1039/c0ib00034e · Cited by 280
Bright-Light Therapy in the Treatment of Mood Disorders
Pail, G., Huf, W., Pjrek, E., Winkler, D., Willeit, M., Praschak-Rieder, N., & Kasper, S. (2011) · Neuropsychobiology · doi:10.1159/000328950 · Cited by 277
Peterson, W. M., Wang, Q., Tzekova, R., & Wiegand, S. J. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-11-04081.2000 · Cited by 267
Deodhar, A., Sliwinska-Stanczyk, P., Xu, H., Baraliakos, X., Gensler, L. S., Fleishaker, D., Wang, L., Wu, J., Menon, S., Wang, C., et al. (2021) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2020-219601 · Cited by 259
Self-citationSTAT1 and STAT3 in tumorigenesis: A matter of balance
Avalle, L., Pensa, S., Regis, G., Novelli, F., & Poli, V. (2012) · JAK-STAT · doi:10.4161/jkst.20045 · Cited by 255
Reich, K., Thyssen, J. P., Blauvelt, A., Eyerich, K., Soong, W., Rice, Z. P., Hong, H. C.-H., Katoh, N., Valenzuela, F., DiBonaventura, M., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(22)01199-0 · Cited by 251
Czimmerer, Z., Daniel, B., Horvath, A., Rückerl, D., Nagy, G., Kiss, M., Peloquin, M., Budai, M. M., Cuaranta-Monroy, I., Simandi, Z., et al. (2018) · Immunity · doi:10.1016/j.immuni.2017.12.010 · Cited by 250
Combe, B., Kivitz, A., Tanaka, Y., van der Heijde, D., Simon, J. A., Baraf, H. S. B., Kumar, U., Matzkies, F., Bartok, B., Ye, L., et al. (2021) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2020-219214 · Cited by 248
Reilley, M. J., McCoon, P., Cook, C., Lyne, P., Kurzrock, R., Kim, Y., Woessner, R., Younes, A., Nemunaitis, J., Fowler, N., et al. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0436-5 · Cited by 245
Leptin signaling in breast cancer: An overview
Cirillo, D., Rachiglio, A. M., la Montagna, R., Giordano, A., & Normanno, N. (2008) · Journal of Cellular Biochemistry · doi:10.1002/jcb.21911 · Cited by 235
VEGF-A in Cardiomyocytes and Heart Diseases
Braile, M., Marcella, S., Cristinziano, L., Galdiero, M. R., Modestino, L., Ferrara, A. L., Varricchi, G., Marone, G., & Loffredo, S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21155294 · Cited by 234
On the origin of myeloid-derived suppressor cells
Millrud, C. R., Bergenfelz, C., & Leandersson, K. (2017) · Oncotarget · doi:10.18632/oncotarget.12278 · Cited by 230
Receptor-mediated cell mechanosensing
Chen, Y., Ju, L., Rushdi, M., Ge, C., & Zhu, C. (2017) · Molecular Biology of the Cell · doi:10.1091/mbc.e17-04-0228 · Cited by 229
Larmonier, N., Marron, M., Zeng, Y., Cantrell, J., Romanoski, A., Sepassi, M., Thompson, S., Chen, X., Andreansky, S., & Katsanis, E. (2006) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-006-0160-8 · Cited by 225
Yu, J., Wang, Y., Yan, F., Zhang, P., Li, H., Zhao, H., Yan, C., Yan, F., & Ren, X. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1400833 · Cited by 219
Epigenetic control of adult stem cell function
Avgustinova, A., & Benitah, S. A. (2016) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2016.76 · Cited by 219
JAK/STAT Cytokine Signaling at the Crossroad of NK Cell Development and Maturation
Gotthardt, D., Trifinopoulos, J., Sexl, V., & Putz, E. M. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02590 · Cited by 211
STAT signaling in the pathogenesis and treatment of leukemias
Lin, T. S., Mahajan, S., & Frank, D. A. (2000) · Oncogene · doi:10.1038/sj.onc.1203486 · Cited by 205
Antov, A., Yang, L., Vig, M., Baltimore, D., & Van Parijs, L. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.7.3435 · Cited by 204
Mechanotransduction in Cardiac Myocytes
LAMMERDING, J., KAMM, R. D., & LEE, R. T. (2004) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1302.005 · Cited by 203
Esashi, E., Wang, Y.-H., Perng, O., Qin, X.-F., Liu, Y.-J., & Watowich, S. S. (2008) · Immunity · doi:10.1016/j.immuni.2008.02.013 · Cited by 202
Hasni, S. A., Gupta, S., Davis, M., Poncio, E., Temesgen-Oyelakin, Y., Carlucci, P. M., Wang, X., Naqi, M., Playford, M. P., Goel, R. R., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-23361-z · Cited by 201
Ruperto, N., Brunner, H. I., Synoverska, O., Ting, T. V., Mendoza, C. A., Spindler, A., Vyzhga, Y., Marzan, K., Grebenkina, L., Tirosh, I., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)01255-1 · Cited by 195
Moskowitz, A. J., Ghione, P., Jacobsen, E., Ruan, J., Schatz, J. H., Noor, S., Myskowski, P., Vardhana, S., Ganesan, N., Hancock, H., et al. (2021) · Blood · doi:10.1182/blood.2021013379 · Cited by 190
Kunisada, K., Hirota, H., Fujio, Y., Matsui, H., Tani, Y., Yamauchi-Takihara, K., & Kishimoto, T. (1996) · Circulation · doi:10.1161/01.cir.94.10.2626 · Cited by 188
Yahata, Y., Shirakata, Y., Tokumaru, S., Yamasaki, K., Sayama, K., Hanakawa, Y., Detmar, M., & Hashimoto, K. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m301866200 · Cited by 183
Liu, Y., Liu, H., Meyer, C., Li, J., Nadalin, S., Königsrainer, A., Weng, H., Dooley, S., & ten Dijke, P. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.478685 · Cited by 181 · cited 1×
“Other studies in human fibroblasts showed that JAK2 has been activated by TGFβ1, then, in turn, phosphorylates STAT3 and leads to its nuclear translocation (Liu et al., 2013).”
BackgroundWang, P.-Y., Yu, J., Lin, J.-H., & Tsai, W.-B. (2011) · Acta Biomaterialia · doi:10.1016/j.actbio.2011.05.021 · Cited by 179
Self-citationHou, Y., Zhu, L., Tian, H., Sun, H.-X., Wang, R., Zhang, L., & Zhao, Y. (2018) · Protein & Cell · doi:10.1007/s13238-018-0505-z · Cited by 179
Sathaliyawala, T., O'Gorman, W. E., Greter, M., Bogunovic, M., Konjufca, V., Hou, Z. E., Nolan, G. P., Miller, M. J., Merad, M., & Reizis, B. (2010) · Immunity · doi:10.1016/j.immuni.2010.09.012 · Cited by 177
HDAC4-Regulated STAT1 Activation Mediates Platinum Resistance in Ovarian Cancer
Stronach, E. A., Alfraidi, A., Rama, N., Datler, C., Studd, J. B., Agarwal, R., Guney, T. G., Gourley, C., Hennessy, B. T., Mills, G. B., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-4111 · Cited by 176 · cited 1×
“However, some studies have also shown that STAT1 can induce platinum resistance in breast cancer, which may be independent of the activation of JAK2/3 (Stronach et al., 2011).”
BackgroundKroon, P., Berry, P. A., Stower, M. J., Rodrigues, G., Mann, V. M., Simms, M., Bhasin, D., Chettiar, S., Li, C., Li, P.-K., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-0874 · Cited by 175
Zhang, W., Liu, Y., Yan, Z., Yang, H., Sun, W., Yao, Y., Chen, Y., & Jiang, R. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000285 · Cited by 173
The Role of JAK/STAT Pathway in Fibrotic Diseases: Molecular and Cellular Mechanisms
Liu, J., Wang, F., & Luo, F. (2023) · Biomolecules · doi:10.3390/biom13010119 · Cited by 172
IFN-γ is required for cytotoxic T cell-dependent cancer genome immunoediting
Takeda, K., NAKAYAMA, M., Hayakawa, Y., Kojima, Y., Ikeda, H., Imai, N., Ogasawara, K., Okumura, K., Thomas, D. M., & Smyth, M. J. (2017) · Nature Communications · doi:10.1038/ncomms14607 · Cited by 171
Osteocytes in bone aging: Advances, challenges, and future perspectives
Cui, J., Shibata, Y., Zhu, T., Zhou, J., & Zhang, J. (2022) · Ageing Research Reviews · doi:10.1016/j.arr.2022.101608 · Cited by 171
Burysek, L., Syrovets, T., & Simmet, T. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m201941200 · Cited by 168
Vincenti, F., Tedesco Silva, H., Busque, S., O’Connell, P., Friedewald, J., Cibrik, D., Budde, K., Yoshida, A., Cohney, S., Weimar, W., et al. (2012) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2012.04127.x · Cited by 168
Bernasconi, A., Marino, R., Ribas, A., Rossi, J., Ciaccio, M., Oleastro, M., Ornani, A., Paz, R., Rivarola, M. A., Zelazko, M., et al. (2006) · Pediatrics · doi:10.1542/peds.2005-2882 · Cited by 167
The involvement of JAK-STAT3 in cell motility, invasion, and metastasis
Teng, Y., Ross, J., & Cowell, J. K. (2014) · JAK-STAT · doi:10.4161/jkst.28086 · Cited by 164
Leptin-Induced JAK/STAT Signaling and Cancer Growth
Mullen, M., & Gonzalez-Perez, R. R. (2016) · Vaccines · doi:10.3390/vaccines4030026 · Cited by 164
Jayaraman, P., Parikh, F., Lopez-Rivera, E., Hailemichael, Y., Clark, A., Ma, G., Cannan, D., Ramacher, M., Kato, M., Overwijk, W. W., et al. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1103553 · Cited by 162
Kodama, H., Fukuda, K., Pan, J., Makino, S., Baba, A., Hori, S., & Ogawa, S. (1997) · Circulation Research · doi:10.1161/01.res.81.5.656 · Cited by 160
Chen, M., Kuan, F., Yen, T., Lu, M., Lin, P.-Y., Chung, Y.-H., Chen, W., & Lee, K. (2014) · Oncotarget · doi:10.18632/oncotarget.2368 · Cited by 158
Wang, P., Yu, H., & Tsai, W. (2010) · Biotechnology and Bioengineering · doi:10.1002/bit.22697 · Cited by 157
Self-citationPan, J., Fukuda, K., Kodama, H., Makino, S., Takahashi, T., Sano, M., Hori, S., & Ogawa, S. (1997) · Circulation Research · doi:10.1161/01.res.81.4.611 · Cited by 155
Wong, A. L., Soo, R. A., Tan, D. S., Lee, S. C., Lim, J. S., Marban, P. C., Kong, L. R., Lee, Y. J., Wang, L. Z., Thuya, W. L., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv026 · Cited by 153
Self-citationO'Donoghue, R. J. J., Knight, D. A., Richards, C. D., Prêle, C. M., Lau, H. L., Jarnicki, A. G., Jones, J., Bozinovski, S., Vlahos, R., Thiem, S., et al. (2012) · EMBO Molecular Medicine · doi:10.1002/emmm.201100604 · Cited by 152 · cited 1×
“, 2004), while IL-6 induced fibrosis by activating STAT3 (O’Donoghue et al., 2012).”
BackgroundHonsho, S., Nishikawa, S., Amano, K., Zen, K., Adachi, Y., Kishita, E., Matsui, A., Katsume, A., Yamaguchi, S., Nishikawa, K., et al. (2009) · Circulation Research · doi:10.1161/circresaha.109.208199 · Cited by 149
Herrmann, A., Kortylewski, M., Kujawski, M., Zhang, C., Reckamp, K. L., Armstrong, B., Wang, L. Q., Kowolik, C. M., Deng, J., Figlin, R. A., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0736 · Cited by 148
Self-citationScreening of rat mesenchymal stem cell behaviour on polydimethylsiloxane stiffness gradients
Wang, P., Tsai, W., & Voelcker, N. H. (2011) · Acta Biomaterialia · doi:10.1016/j.actbio.2011.09.030 · Cited by 145
Self-citationAltered phenotype in peripheral blood and tumor-associated NK cells from colorectal cancer patients
Rocca, Y., Roberti, M. P., Arriaga, J. M., Amat, M., Bruno, L. I., Pampena, M. B., Huertas, E., Loria, F. S., Pairola, A., Bianchini, M., et al. (2012) · Innate Immunity · doi:10.1177/1753425912453187 · Cited by 144
Ostrand‐Rosenberg, S., Grusby, M. J., & Clements, V. K. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.165.11.6015 · Cited by 143
Dual Roles of IL-27 in Cancer Biology and Immunotherapy
Fabbi, M., Carbotti, G., & Ferrini, S. (2017) · Mediators of Inflammation · doi:10.1155/2017/3958069 · Cited by 142
Harrison, C. N., Garcia, J. S., Somervaille, T. C. P., Foran, J. M., Verstovšek, S., Jamieson, C. H. M., Mesa, R. A., Ritchie, E. K., Tantravahi, S. K., Vachhani, P., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.02188 · Cited by 141
Gough, D. J., Koetz, L., & Levy, D. E. (2013) · PLoS ONE · doi:10.1371/journal.pone.0083395 · Cited by 138
Harir, N., Pecquet, C., Kerenyi, M. A., Sonneck, K., Kovačic, B., Nyga, R., Brevet, M., Dhennin, I., Gouilleux‐Gruart, V., Beug, H., et al. (2006) · Blood · doi:10.1182/blood-2006-01-029918 · Cited by 138
Damsky, W., Wang, A., Kim, D. J., Young, B. D., Singh, K., Murphy, M. J., Daccache, J. A., Clark, A., Ayasun, R., Ryu, C., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-30615-x · Cited by 138
Dufva, O., Kankainen, M., Kelkka, T., Sekiguchi, N., Awad, S. A., Eldfors, S., Yadav, B., Kuusanmäki, H. A., Malani, D., Andersson, E. I., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-03987-2 · Cited by 137
Helix 8 is the essential structural motif of mechanosensitive GPCRs
Erdogmus, S., Storch, U., Danner, L., Becker, J., Winter, M., Ziegler, N., Wirth, A., Offermanns, S., Hoffmann, C., Gudermann, T. W., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-13722-0 · Cited by 137
Chemokines integrate JAK/STAT and G‐protein pathways during chemotaxis and calcium flux responses
Soriano, S. F., Serrano, A., Hernanz‐Falcón, P., de Ana, A. M., Monterrubio, M., Martínez‐A, C., Rodríguez-Frade, J. M., & Mellado, M. (2003) · European Journal of Immunology · doi:10.1002/eji.200323897 · Cited by 135
Seko, Y., Seko, Y., Takahashi, N., Shibuya, M., & Yazaki, Y. (1999) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1998.9969 · Cited by 134
STAT proteins: a kaleidoscope of canonical and non-canonical functions in immunity and cancer
Awasthi, N., Liongue, C., & Ward, A. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01214-y · Cited by 134
Ram, P. T., & Iyengar, R. (2001) · Oncogene · doi:10.1038/sj.onc.1204186 · Cited by 133
GPCR-Hippo Signaling in Cancer
Luo, J., & Yu, F. (2019) · Cells · doi:10.3390/cells8050426 · Cited by 130
Phase I Study of OPB-31121, an Oral STAT3 Inhibitor, in Patients with Advanced Solid Tumors
Oh, D., Lee, S., Han, S., Kim, M., Kim, T.-M., Kim, T., Heo, D. S., Yuasa, M., Yanagihara, Y., & Bang, Y. (2015) · Cancer Research and Treatment · doi:10.4143/crt.2014.249 · Cited by 128
Zhu, S., Liu, M., Bennett, S., Wang, Z., Pfleger, K. D. G., & Xu, J. (2021) · Journal of Cellular Physiology · doi:10.1002/jcp.30375 · Cited by 128
Salminen, A., Kauppinen, A., & Kaarniranta, K. (2019) · Journal of Molecular Medicine · doi:10.1007/s00109-019-01795-9 · Cited by 127
Loss of STAT3 in murine NK cells enhances NK cell–dependent tumor surveillance
Gotthardt, D., Putz, E. M., Straka, E., Kudweis, P., Biaggio, M., Poli, V., Strobl, B., Müller, M. M., & Sexl, V. (2014) · Blood · doi:10.1182/blood-2014-03-564450 · Cited by 124
Reddy, D., Kumavath, R., Ghosh, P., & Barh, D. (2019) · Biomolecules · doi:10.3390/biom9120792 · Cited by 124
Ogura, M., Uchida, T., Terui, Y., Hayakawa, F., Kobayashi, Y., Taniwaki, M., Takamatsu, Y., Naoe, T., Tobinai, K., Munakata, W., et al. (2015) · Cancer Science · doi:10.1111/cas.12683 · Cited by 123
Smeekens, S. P., Plantinga, T. S., van de Veerdonk, F. L., Heinhuis, B., Hoischen, A., Joosten, L. A. B., Arkwright, P. D., Gennery, A. R., Kullberg, B. J., Veltman, J. A., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0029248 · Cited by 123
Li, J. (2013) · JAK-STAT · doi:10.4161/jkst.23930 · Cited by 120
Type I Interferons as Regulators of Human Antigen Presenting Cell Functions
Gessani, S., Conti, L., Cornò, M. D., & Belardelli, F. (2014) · Toxins · doi:10.3390/toxins6061696 · Cited by 119
Cross talk between signaling and vitamin A transport by the retinol-binding protein receptor STRA6
Berry, D. C., O'Byrne, S. M., Vreeland, A. C., Blaner, W. S., & Noy, N. (2012) · Molecular and Cellular Biology · doi:10.1128/mcb.00505-12 · Cited by 116
Bendell, J. C., Hong, D. S., Burris, H. A., Naing, A., Jones, S. F., Falchook, G., Bricmont, P., Elekes, A., Rock, E. P., & Kurzrock, R. (2014) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-014-2480-2 · Cited by 115
AZD1480: A Phase I Study of a Novel JAK2 Inhibitor in Solid Tumors
Plimack, E. R., LoRusso, P. M., Mccoon, P. E., Tang, W., Krebs, A. D., Curt, G. A., & Eckhardt, S. (2013) · The Oncologist · doi:10.1634/theoncologist.2013-0198 · Cited by 115
Fleischmann, R., DAMJANOV, N. S., Kivitz, A., Legedza, A. K., Hoock, T. C., & Kinnman, N. (2014) · Arthritis & Rheumatology · doi:10.1002/art.38949 · Cited by 114
Lee, K., Hsu, E., Guh, J., Yang, M., Wang, D.-S., Kulp, S. K., Shapiro, C. L., & Chen, C. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.264598 · Cited by 114
Wu, L., Deng, Z., Peng, Y., Han, L., Liu, J., Wang, L., Li, B., Zhao, J., Jiao, S., & Wei, H. (2017) · Oncotarget · doi:10.18632/oncotarget.20164 · Cited by 114
Self-citationThorn, M., Guha, P., Cunetta, M., Espat, N. J., Miller, G., Junghans, R. P., & Katz, S. C. (2016) · Cancer Gene Therapy · doi:10.1038/cgt.2016.19 · Cited by 113
Targeting STAT3 with silibinin to improve cancer therapeutics
Bosch‐Barrera, J., Queralt, B., & Menéndez, J. A. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.06.003 · Cited by 113
Mechanotransduction and nuclear function
Graham, D. M., & Burridge, K. (2016) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2016.03.006 · Cited by 111
Vargas‐Hernández, A., Mace, E. M., Zimmerman, O., Zerbe, C. S., Freeman, A. F., Rosenzweig, S. D., Leiding, J. W., Torgerson, T. R., Altman, M. C., Schussler, E., et al. (2017) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2017.08.040 · Cited by 106
Targeting the JAK/STAT Signaling Pathway for Breast Cancer
Shao, F., Pang, X., & Baeg, G. H. (2020) · Current Medicinal Chemistry · doi:10.2174/0929867328666201207202012 · Cited by 106
Liu, Y., Wang, L., Li, S., Zhang, T., Chen, C., Hu, J., Sun, D., & Lü, H. (2022) · Journal of Orthopaedic Translation · doi:10.1016/j.jot.2022.08.008 · Cited by 106
Self-citationLittle, P. R., King, V. L., Davis, K. R., Cosgrove, S. B., & Stegemann, M. R. (2014) · Veterinary Dermatology · doi:10.1111/vde.12186 · Cited by 105
The JAK1/STAT3/SOCS3 axis in bone development, physiology, and pathology
Sims, N. A. (2020) · Experimental & Molecular Medicine · doi:10.1038/s12276-020-0445-6 · Cited by 104
IL-2 Induces STAT4 Activation in Primary NK Cells and NK Cell Lines, But Not in T Cells
Wang, K. S., Ritz, J., & Frank, D. A. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.162.1.299 · Cited by 103
Li, H. S., Yang, C. Y., Nallaparaju, K. C., Zhang, H., Liu, Y., Goldrath, A. W., & Watowich, S. S. (2012) · Blood · doi:10.1182/blood-2012-07-441311 · Cited by 103
Patel, M. R., Dash, A., Jacobson, B. A., Ji, Y., Baumann, D. C., Ismail, K., & Kratzke, R. A. (2019) · Cancer Gene Therapy · doi:10.1038/s41417-018-0074-6 · Cited by 96
Suppressing STAT5 signaling affects osteosarcoma growth and stemness
Subramaniam, D., Angulo, P., Ponnurangam, S., Dandawate, P. R., Ramamoorthy, P., Pugazhendhi, S., Iwakuma, T., Weir, S. J., Chastain, K. M., & Anant, S. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-2335-1 · Cited by 95
Worm, M., Thyssen, J. P., Schliemann, S., Bauer, A., Shi, V. Y., Ehst, B., Tillmann, S., Korn, S., Resen, K., & Agner, T. (2022) · British Journal of Dermatology · doi:10.1111/bjd.21037 · Cited by 94
IL-10 subfamily members: IL-19, IL-20, IL-22, IL-24 and IL-26
Conti, P., Kempuraj, D., Frydas, S., Kandere‐Grzybowska, K., Boucher, W. S., Létourneau, R., Madhappan, B., Sagimoto, K., Christodoulou, S., & Theoharides, T. C. (2003) · Immunology Letters · doi:10.1016/s0165-2478(03)00087-7 · Cited by 93
Álvaro, T., Lejeune, M., Camacho, F. I., Salvadó, M. T., Sánchez, L., García, J. F., López, C., Jaén, J., Bosch, R., Pons, L. E., et al. (2006) · PubMed · Cited by 93
Yang, R., Lirussi, D., Thornton, T. M., Jelley-Gibbs, D. M., Diehl, S. A., Case, L. K., Madesh, M., Taatjes, D. J., Teuscher, C., Haynes, L., et al. (2015) · eLife · doi:10.7554/elife.06376 · Cited by 91
Xiao, J., Gong, Y., Chen, Y., Yu, D., Wang, X., Zhang, X., Dou, Y., Liu, D., Cheng, G., Lu, S., et al. (2017) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00428.2016 · Cited by 91
Khanna, D., Padilla, C. M., Tsoi, L. C., Nagaraja, V., Khanna, P. P., Tabib, T., Kahlenberg, J. M., Young, A., Huang, S., Gudjonsson, J. E., et al. (2022) · JCI Insight · doi:10.1172/jci.insight.159566 · Cited by 91
de Groot, J., Liang, J., Kong, L.-Y., Wei, J., Piao, Y., Fuller, G. N., Qiao, W., & Heimberger, A. B. (2012) · Oncotarget · doi:10.18632/oncotarget.663 · Cited by 90
Villarino, A. V., Sciumé, G., Davis, F. P., Iwata, S., Zitti, B., Robinson, G., Hennighausen, L., Kanno, Y., & O'Shea, J. (2017) · Journal of Experimental Medicine · doi:10.1084/jem.20150907 · Cited by 90
Kong, L.-Y., Wei, J., Sharma, A. K., Barr, J., Abou-Ghazal, M. K., Fokt, I., Weinberg, J. S., Rao, G., Grimm, E. A., Priebe, W., et al. (2008) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-008-0618-y · Cited by 89
Regulation of Natural Killer Cell Function by STAT3
Cacalano, N. A. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00128 · Cited by 89
Ding, S., Kingshott, P., Thissen, H. W., Pera, M. F., & Wang, P. (2016) · Biotechnology and Bioengineering · doi:10.1002/bit.26075 · Cited by 89
Self-citationZhu, S., Phatarpekar, P. V., Denman, C. J., Senyukov, V., Somanchi, S. S., Nguyen-Jackson, H. T., Mace, E. M., Freeman, A. F., Watowich, S. S., Orange, J. S., et al. (2014) · Blood · doi:10.1182/blood-2013-05-499707 · Cited by 87
Regulation of Angiotensin II-induced Phosphorylation of STAT3 in Vascular Smooth Muscle Cells
Liang, H., Venema, V. J., Wang, X., Ju, H., Venema, R. C., & Marrero, M. B. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.28.19846 · Cited by 87
Wang, P., Thissen, H. W., & Kingshott, P. (2016) · Acta Biomaterialia · doi:10.1016/j.actbio.2016.08.054 · Cited by 86
Self-citationMechanically activated ion channels
Martinac, B., & Poole, K. (2018) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2018.02.011 · Cited by 85
Targeting signaling pathways in multiple myeloma: Pathogenesis and implication for treatments
Hu, J., & Hu, W.-X. (2018) · Cancer Letters · doi:10.1016/j.canlet.2017.11.020 · Cited by 84 · cited 2×
“, 2018), multiple myeloma (Hu and Hu, 2018), lymphoma (von Hoff et al.”
BackgroundMankan, A., & Greten, F. (2011) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2011.601739 · Cited by 83
JAK–STAT inhibition impairs K‐RAS‐driven lung adenocarcinoma progression
Mohrherr, J., Haber, M., Breitenecker, K., Aigner, P., Moritsch, S., Voronin, V., Eferl, R., Moriggl, R., Stoiber, D., Győrffy, B., et al. (2019) · International Journal of Cancer · doi:10.1002/ijc.32624 · Cited by 80
The Role of JAK/STAT Molecular Pathway in Vascular Remodeling Associated with Pulmonary Hypertension
Roger, I., Milara, J., Montero, P., & Cortijo, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094980 · Cited by 80
Bagratuni, T., Mavrianou, N., Gavalas, N. G., Tzannis, K., Arapinis, C., Liontos, M., Christodoulou, M., Thomakos, N., Haidopoulos, D. A., Rodolakis, A., et al. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2019.11.017 · Cited by 79
Boyle, K., Zhang, J., Nicholson, S. E., Trounson, E., Babon, J. J., McManus, E. J., Nicola, N. A., & Robb, L. G. (2008) · Cellular Signalling · doi:10.1016/j.cellsig.2008.11.002 · Cited by 78
Gao, L., Xu, D.-Q., Wen, L., Zhang, X., Shao, Y., & Zhao, X. (2005) · Acta Pharmacologica Sinica · doi:10.1111/j.1745-7254.2005.00053.x · Cited by 77
Jakubzick, C., Choi, E. S., Carpenter, K. J., Kunkel, S. L., Evanoff, H. L., Martínez, F. J., Flaherty, K. R., Toews, G. B., Colby, T. V., Travis, W. D., et al. (2004) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)63759-5 · Cited by 76
STAT3/5 Inhibitors Suppress Proliferation in Bladder Cancer and Enhance Oncolytic Adenovirus Therapy
Hindupur, S. V., Schmid, S. C., Koch, J. A., Youssef, A., Baur, E.-M., Wang, D., Horn, T. D., Slotta‐Huspenina, J., Gschwend, J. E., Holm, P. S., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21031106 · Cited by 76
Sen, M., Pollock, N., Black, J., DeGrave, K. A., Wheeler, S., Freilino, M. L., Joyce, S. C., Lui, V. W. Y., Zeng, Y., Chiosea, S. I., et al. (2015) · Neoplasia · doi:10.1016/j.neo.2015.01.003 · Cited by 75
Stat3-siRNA induces Fas-mediated apoptosis in vitro and in vivo in breast cancer
Rao (2009) · International Journal of Oncology · doi:10.3892/ijo_00000249 · Cited by 75
Xiong, H., Su, W., Liang, Q., Zhang, Z., Chen, H., Du, W., Chen, Y., & Fang, J. (2009) · Laboratory Investigation · doi:10.1038/labinvest.2009.11 · Cited by 74
Shahrara, S., Amin, M. A., Woods, J. M., Haines, G. K., & Koch, A. E. (2003) · Arthritis & Rheumatism · doi:10.1002/art.11344 · Cited by 74
Mesa, R. A., Harrison, C. N., Oh, S. T., Gerds, A. T., Gupta, V. K., Catalano, J. V., Cervantes, F., Devos, T., Hus, M., Kiladjian, J., et al. (2022) · Leukemia · doi:10.1038/s41375-022-01637-7 · Cited by 73
Direct effects of T‐bet and MHC class I expression, but not STAT1, on peripheral NK cell maturation
Robbins, S. H., Tessmer, M. S., Kaer, L. V., & Brossay, L. (2005) · European Journal of Immunology · doi:10.1002/eji.200425797 · Cited by 67
Inhibition of JAK2 Signaling by TG101209 Enhances Radiotherapy in Lung Cancer Models
Sun, Y., Moretti, L., Giacalone, N. J., Schleicher, S. M., Speirs, C. K., Carbone, D. P., & Lü, B. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31820d9d11 · Cited by 67
Kunnen, S. J., Malas, T. B., Semeins, C. M., Bakker, A. D., & Peters, D. J. M. (2017) · Journal of Cellular Physiology · doi:10.1002/jcp.26222 · Cited by 67
Woods, D. M., Ramakrishnan, R., Laino, A. S., Berglund, A., Walton, K., Betts, B. C., & Weber, J. S. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1100 · Cited by 66
Wang, T.-L., Yang, Y.-H., Chang, H., & Hung, C.-R. (2004) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2004.06.016 · Cited by 65
Paukku, K., Valgeirsdóttir, S., Saharinen, P., Bergman, M., Heldin, C., & Silvennoinen, O. (2000) · Biochemical Journal · doi:10.1042/bj3450759 · Cited by 65
Dalagiorgou, G., Piperi, C., Adamopoulos, C., Georgopoulou, U., Gargalionis, A. N., Spyropoulou, A., Zoi, I., Nokhbehsaim, M., Damanaki, A., Deschner, J., et al. (2016) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-016-2394-8 · Cited by 63
Phase 2 study of gandotinib (LY2784544) in patients with myeloproliferative neoplasms
Berdeja, J. G., Palandri, F., Baer, M. R., Quick, D. P., Kiladjian, J., Martinelli, G., Verma, A. K., Hamid, O., Walgren, R. A., Pitou, C., et al. (2018) · Leukemia Research · doi:10.1016/j.leukres.2018.06.014 · Cited by 63
Liang, X., Huang, X., Zhou, Y., Jin, R., & Li, Q. (2016) · Stem Cells Translational Medicine · doi:10.5966/sctm.2015-0274 · Cited by 62
Ruxolitinib Cream in the Treatment of Cutaneous Lichen Planus: A Prospective, Open-Label Study
Brumfiel, C. M., Patel, M. H., Severson, K. J., Zhang, N., Li, X., Quillen, J. K., Zunich, S. M., Branch, E. L., Nelson, S. A., Pittelkow, M. R., et al. (2022) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2022.01.015 · Cited by 62
Cited by
Interplay of oxidative stress, cellular communication and signaling pathways in cancer
Iqbal, M. J., Kabeer, A., Abbas, Z., Siddiqui, H. A., Calina, D., Sharifi-Rad, J., & Cho, W. C. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-023-01398-5 · Cited by 418
Metadata
- Authors
- Hu, Q., Bian, Q., Rong, D., Wang, L., Song, J., Huang, H.-S., Zeng, J., Mei, J., & Wang, P.-Y.
- Venue
- Frontiers in Bioengineering and Biotechnology
- Publisher
- Frontiers Media SA
- Published
- 2023-02-23
- Volume
- 11
- Pages
- 1110765-1110765
- ISSN
- 2296-4185 (ISSN-L)
- OpenAlex
- W4321599241
- Cited by
- 339
- References
- 258
- FWCI
- 34.99
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.